The Mycoplasma Testing Market covers technologies, kits, instruments, and testing services used to identify mycoplasma contamination in cell cultures, biopharmaceutical products, and research materials. Because mycoplasma can grow without being easily detected by routine visual inspection, reliable testing plays an important role in maintaining the quality, safety, and consistency of biological research and drug manufacturing.
Mycoplasma testing is especially important across pharmaceutical and biotechnology manufacturing, cell and gene therapy development, vaccine production, academic research, and quality-control laboratories. The market is increasingly moving toward faster molecular testing methods, including PCR-based and digital PCR technologies, as manufacturers seek quicker and more reliable contamination detection.
According to Market Research Future, the global market was valued at approximately USD 1.21 billion in 2025 and is projected to reach USD 3.52 billion by 2035, representing a 10.20% CAGR during 2026–2035. North America currently accounts for the largest share, while Asia-Pacific is expected to experience rapid expansion.
Get Free Sample PDF Brochure:
https://www.marketresearchfuture.com/sample_request/6776
Market Drivers
Rising Biopharmaceutical Production
The continued expansion of pharmaceutical and biotechnology manufacturing is creating greater demand for dependable contamination testing. As more biologic drugs, vaccines, and advanced therapies move through development and commercial production, manufacturers need routine testing throughout different stages of the production process.
Growing Cell and Gene Therapy Development
The rapid development of cell and gene therapies is becoming an important growth factor for the market. These therapies often involve sensitive cell-based manufacturing processes where contamination control is essential. As the number of clinical programs and commercial products increases, the need for reliable mycoplasma screening is also expanding.
Shift Toward Rapid Molecular Testing
Traditional culture-based methods can require lengthy incubation periods. In contrast, PCR-based technologies can provide results much faster, making them attractive to manufacturers that want to reduce testing delays and improve production efficiency.
Quantitative PCR currently represents a major technology segment, while digital PCR and other advanced molecular platforms are gaining attention because of their sensitivity and ability to support automated workflows.
Increasing Regulatory Focus on Product Quality
Regulatory requirements surrounding biologics manufacturing and contamination control are encouraging pharmaceutical and biotechnology companies to strengthen their quality-control procedures. Regular mycoplasma testing helps manufacturers demonstrate that cell cultures and biological products meet required quality and safety standards.
Expansion of Contract Testing Services
Many small and mid-sized biotechnology companies prefer outsourcing specialized quality-control testing instead of building and maintaining their own advanced laboratories. This trend is supporting the growth of contract testing organizations and specialized laboratory service providers.
MRFR estimates that testing services will expand at a 13.05% CAGR through 2035, reflecting increasing outsourcing activity.
Market Challenges
High Cost of Advanced Testing Platforms
Advanced PCR and automated testing systems can require considerable upfront investment. Smaller biotechnology companies, academic laboratories, and research facilities may find it difficult to justify these costs, particularly when their testing volumes are relatively low.
Shortage of Skilled Laboratory Professionals
Modern molecular testing requires trained personnel who understand PCR workflows, contamination control, laboratory procedures, and regulatory requirements. A shortage of experienced professionals can make it challenging for laboratories to implement and maintain advanced testing systems.
Lengthy Validation and Method-Transfer Requirements
Introducing a new testing technology into a regulated manufacturing environment often requires extensive validation and documentation. These requirements can increase implementation time and costs for pharmaceutical and biotechnology companies.
Competition Between Testing Technologies
Although molecular methods are gaining popularity, conventional culture-based approaches remain established in many laboratories. The coexistence of different testing technologies can slow the transition toward newer platforms in some markets.
Regulatory Differences Across Regions
Regulatory expectations for mycoplasma detection are not equally developed in every market. Differences in testing standards and validation requirements can create additional challenges for companies operating across multiple countries.
Market Segmentation
By Product and Service
Kits and Reagents:
Kits and reagents represent an important portion of the market because routine testing requires recurring consumables such as extraction reagents, PCR components, controls, and related laboratory materials.
Instruments:
Testing instruments include PCR systems, digital PCR platforms, and other laboratory equipment used to detect mycoplasma contamination.
Testing Services:
Specialized laboratories and contract testing organizations provide mycoplasma detection services to pharmaceutical companies, biotechnology firms, and research institutions that prefer outsourcing their testing requirements.
MRFR reports that kits and reagents held the leading revenue position in 2025, while testing services are expected to record strong growth during the forecast period.
By Technology
PCR Testing:
PCR-based testing provides rapid and sensitive detection and has become an important approach for routine contamination screening.
ELISA Testing:
ELISA-based methods can be used for detecting mycoplasma-related biological markers and remain part of the available testing landscape.
Culture Testing:
Culture-based techniques are established microbiological methods for detecting contamination, although they generally require more time than rapid molecular approaches.
Nucleic Acid Hybridization:
These techniques use nucleic-acid-based detection approaches and can provide another option for identifying mycoplasma contamination.
Quantitative PCR accounted for approximately 59.10% of the market in 2025, while digital PCR is projected to experience rapid growth during the forecast period.
By Application
Cell-Line Quality Control:
Cell-line quality control is a major application because pharmaceutical and biotechnology manufacturers need to ensure that cell banks remain free from contamination during development and production.
Gene and Cell Therapy Manufacturing:
The expanding cell and gene therapy pipeline is increasing the need for contamination testing at multiple stages of manufacturing.
Final Product Release Testing:
Testing may be performed before the release of biological products to help verify that manufacturing batches meet quality requirements.
Research and Development:
Academic institutions, biotechnology companies, and research laboratories use mycoplasma testing to protect the integrity of cell-based experiments.
By End User
Pharmaceutical Companies:
Pharmaceutical manufacturers use mycoplasma testing as part of quality-control and manufacturing processes.
Biotechnology Companies:
Biotechnology firms represent a major user group, particularly those involved in biologics, cell therapies, and advanced biological products.
Contract Manufacturing Organizations:
CMOs and CDMOs are increasingly incorporating specialized contamination testing into their manufacturing and quality-control services.
Academic and Research Institutes:
Research organizations use mycoplasma testing to ensure the reliability and reproducibility of cell culture-based studies.
MRFR indicates that biopharma and biotechnology companies represented the largest end-user category in 2025, while contract manufacturing organizations are showing strong growth.
By Region
North America
North America represents the largest regional market, supported by a strong pharmaceutical and biotechnology sector, advanced laboratory infrastructure, and established regulatory frameworks. The U.S. accounts for a substantial portion of regional demand due to its large biologics manufacturing base and significant investment in cell and gene therapies.
Europe
Europe remains an important market because of its established pharmaceutical industry, advanced biotechnology ecosystem, and strong focus on manufacturing quality and regulatory compliance. Countries such as Germany, France, and the UK contribute significantly to regional demand.
Asia-Pacific
Asia-Pacific is emerging as one of the fastest-growing regions for mycoplasma testing. Expanding pharmaceutical manufacturing, biotechnology investments, clinical research, and biologics production in countries such as China, India, Singapore, Japan, and South Korea are supporting market development.
MRFR projects Asia-Pacific to grow at approximately 16.50% CAGR through 2035, making it a key expansion region for the industry.
Latin America, Middle East & Africa
These regions represent developing opportunities as pharmaceutical manufacturing capabilities, healthcare infrastructure, and biotechnology investments continue to improve. Greater adoption of international quality standards is also expected to support demand for contamination testing.
Regional Insights
North America
The North American market is supported by a mature biopharmaceutical manufacturing ecosystem and high adoption of advanced molecular testing technologies. Strong regulatory oversight and continued development of cell and gene therapies are also contributing to demand.
Europe
European demand is being supported by pharmaceutical manufacturing, contract development and manufacturing organizations, and continued attention to sterile and aseptic production practices.
Asia-Pacific
The region is seeing increasing investments in biomanufacturing facilities and laboratory infrastructure. India and China, in particular, are expanding their pharmaceutical and biotechnology capabilities, creating additional opportunities for mycoplasma testing providers.
Rest of the World
Latin America, the Middle East, and Africa are gradually developing their biotechnology and pharmaceutical capabilities. As local manufacturing and research activities expand, the requirement for reliable quality-control testing is expected to increase.
Key Players
Roche Diagnostics
Charles River Laboratories
Lonza Group
Thermo Fisher Scientific
Merck KGaA
SGS SA
bioMérieux
Eurofins Scientific
Sartorius
PromoCell
These companies participate in areas such as mycoplasma detection technologies, laboratory testing, reagents, molecular assays, and related quality-control solutions.
Future Outlook
The Mycoplasma Testing Market is expected to continue expanding as pharmaceutical and biotechnology companies increase their focus on contamination control, manufacturing quality, and faster product-release processes.
The industry is gradually moving from traditional testing approaches toward rapid molecular technologies, automated workflows, digital PCR, and integrated laboratory systems. The continued development of cell and gene therapies is also expected to create additional testing requirements across research, clinical development, and commercial manufacturing.
Another important trend is the growing use of outsourced testing services. Smaller biotechnology companies and research organizations can access specialized testing capabilities without making large investments in laboratory infrastructure.
Looking ahead, automation, rapid molecular detection, advanced analytics, and improved laboratory workflows are expected to play an increasingly important role in shaping the market.
Related Report:
Understand industry shifts with well-researched analysis:
Hair Transplant Market Forecast
Healthcare Consulting Services Market Outlook
Healthcare Consulting Services Market Analysis
Healthcare Consulting Services Market Distribution
About Market Research Future:
Market Research Future (MRFR) is a global market research company providing research and strategic insights across a wide range of industries. Its reports cover markets at global, regional, and country levels, with analysis based on products, technologies, applications, end users, and market participants.
Contact:
Market Research Future (Part of Wantstats Research and Media Private Limited)
99 Hudson Street, 5th Floor
New York, NY 10013
United States of America
+1 628 258 0071 (US)
+44 2035 002 764 (UK)
Email: sales@marketresearchfuture.com
Website: https://www.marketresearchfuture.com
